Click on the title to see the full article:
Adalimumab for nail psoriasis: Efficacy and safety from the first 26 weeks of a phase 3, randomized, placebo-controlled trial
Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with difficult to treat nail and scalp psoraisis Results of 2 phase III randomized, controlled trials (ESTEEM 1 and ESTEEM
Efficacy and safety of mirikizumab LY3074828 in thetreatment of moderate to severe plaque psoriasis resultsfrom a randomized phase II study
Esteem poster- EADV and Australian College of Derms
Improvement of scalp and nail lesions with ixekizumab in a phase 2 trial in patients with chronic plaque psoriasis
Infectious, Oncologic, and Autoimmune Comorbidities of Psoriasis and Psoriatic Arthritis
Ixekizumab treatment improves fingernail psoriasis in patients with moderate-to-severe psoriasis: results from the randomized, controlled and open-label phases of UNCOVER-3
Primary efficacy and safety of adalimumab in nail psoriasis from the first 26 weeks of a phase-3, randomized, placebo-controlled trial with subanalysis in patients with and without psoriatic arthritis
Secukinumab Efficacy Stratified by Body Weight: A Subanalysis From the ERASURE Phase 3 Study in Psoriasis
Secukinumab induction and maintenance therapy in moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled, phase II regimen-finding study
Secukinumab provides better relief from the impact of psoriasis on daily activities and personal relationships than etanercept: results of two phase 3 placebo-controlled randomized clinical trials in moderate-to-severe psoriasis
Secukinumab Provides Complete or Almost-complete Psoriasis Clearance in Moderate-to-Severe Plaque Psoriasis: Pooled Analysis of 4 Phase 3 Trials
Secukinumab shows efficacy in subjects with and without previous exposure to biologic psoriasis therapy subanalysis from the phase 3 FIXTURE study
